Arzerra outperformed by business partner
Pharmacyclics and Janssen's drug ibrutinib outperforms Arzerra by Danish Genmab and its partner GlaxoSmithKline, according to new data.
BY BENJAMIN WERNER CHRISTENSEN
The risk of progression or death among patients treated with the drug ibrutinib compared to Arzerra (ofatumumab) was reduced by 79 percent, according to data from a comprehensive phase 3 study presented today at ASCO on Tuesday by Janssen and Pharmacyclics, says Janssen in a corporate statement.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab’s drug hope is failing
For abonnenter
Genmab CEO: A year focused on daratumumab
For abonnenter
